Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News LadRx Corp LADX

Healthcare Biotechnology
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an... see more

Recent & Breaking News (OTCQB:LADX)

LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License

Business Wire June 3, 2024

LadRx Issues 2024 Update to Shareholders

Business Wire January 9, 2024

LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation

Business Wire June 22, 2023

LadRx Announces Reverse Stock Split Effective as of May 17, 2023

Business Wire May 18, 2023

LadRx Announces Reverse Stock Split

Business Wire May 10, 2023

LadRx Highlights Patent Issued for Its LADR Technology

Business Wire March 27, 2023

LadRx Announces Review of Strategic Alternatives and Provides Corporate Updates

Business Wire March 15, 2023

LadRx Corporation Issues Corporate Update for 3Q22

Business Wire November 17, 2022

LadRx Corporation Announces OTCQB Ticker Change to LADX

Business Wire October 5, 2022

CytRx Corporation Relaunches as LadRx Corporation

Business Wire September 23, 2022

European Patent Office Awards CytRx Key Patent

Business Wire September 7, 2022

CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors

Business Wire August 9, 2022

CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock

Business Wire May 19, 2022

CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.

Business Wire May 17, 2022

CytRx Partners with Oncology Development Expert to Advance LADR Platform

Business Wire April 20, 2022

CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress

Business Wire March 21, 2022

CytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates

Business Wire March 9, 2022

CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C

Business Wire February 24, 2022

CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C

Business Wire February 14, 2022

CytRx to Hold Town Hall for Stockholders on Thursday, January 20th

Business Wire January 18, 2022